Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xlife Sciences AGXSWX:XLS -3.75%37 Price-to-Tangible-Book is 2.70 as of Aug. 14, 2026, which is 36% below its 10-year median of 4.19. GuruFocus rates XSWX:XLS with a GF Score™ of 37/100 and a GF Value™ of CHF7.08 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,141 Biotechnology companies, Xlife Sciences AG ranks better than 57.49% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Xlife Sciences AG Price-to-Tangible-Book Related Terms
Xlife Sciences AG Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, RVMD: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Xlife Sciences AG (XSWX:XLS) has a Price-to-Tangible-Book of 2.70 as of Aug. 14, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Xlife Sciences AG and its competitors. This is 36% below median its historical median of 4.19. Over the past decade, Xlife Sciences AG's Price-to-Tangible-Book has ranged from 2.71 to 4.34. According to the industry distribution chart, Xlife Sciences AG ranks #485 out of 1141 companies in the Biotechnology industry, placing it in the top 42.5%.
Is Xlife Sciences AG's Price-to-Tangible-Book too high?
Xlife Sciences AG's current Price-to-Tangible-Book of 2.70 is 36% below median its 10-year median of 4.19. Over the past 10 years, this metric has ranged from a low of 2.71 to a high of 4.34. The Biotechnology industry median Price-to-Tangible-Book is 3.24. Xlife Sciences AG's value of 2.70 is 16.7% below this industry median. Based on the distribution chart, Xlife Sciences AG ranks #485 out of 1141 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #485 out of 1141 companies for Price-to-Tangible-Book. This puts Xlife Sciences AG in the upper half of its industry. The industry median Price-to-Tangible-Book is 3.24. Xlife Sciences AG's value of 2.70 is 16.7% below this benchmark. Historically, Xlife Sciences AG's own Price-to-Tangible-Book has ranged from 2.71 to 4.34 over the past decade. While the company's 10-year median is 4.19 vs. the industry median of 3.24, Xlife Sciences AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.24, based on 1,141 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Price-to-Tangible-Book of 2.70 is 16.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Price-to-Tangible-Book is 2.70, which is 36% below median its own 10-year median of 4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.08, compared to a current price of CHF15.40 — trading 117.5% above its estimated fair value. The current Price-to-Tangible-Book is 2.70, which is 36% below median its 10-year median of 4.19 and 16.7% below the Biotechnology industry median of 3.24. Xlife Sciences AG's overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Price-to-Tangible-Book is 2.70 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF15.40 is trading 117.5% above its estimated GF Value™ of CHF7.08.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Price-to-Tangible-Book: 2.70 (36% below median its 10-year median of 4.19)
GF Value™: CHF7.08 vs. price of CHF15.40 (117.5% above fair value)
Industry Position: 16.7% below the Biotechnology median (#485 of 1141)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
37GF Score
Get the complete analysis for XSWX:XLS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
